Myelofibrosis

• CLINICAL_TRIALS withdrawal · 2026-01-05
  Clinical Trial Update: A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) [Phase 1, Phase 2]

  A Phase 1/Phase 2 clinical trial evaluating TQ05105 in combination with TQB3909 for myelofibrosis was terminated. No results are provided in…

• CLINICAL_TRIALS withdrawal · 2025-05-22
  Clinical Trial Update: A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis [Phase 2]

  A Phase 2 trial evaluating INCB57643 in combination with ruxolitinib for myelofibrosis in JAK inhibitor-naïve patients has been withdrawn.

• EMA withdrawal · 2017-06-09
  EMA Application withdrawn: Enpaxiq — CTI Life Sciences Limited

  The EMA withdrawn the application for Enpaxiq by CTI Life Sciences Limited, with the primary indication in myelofibrosis.

• CLINICAL_TRIALS withdrawal · 2017-05-08
  Clinical Trial Update: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) [Phase 1]

  A Phase 1 trial evaluating pacritinib in combination with low-dose decitabine for intermediate-high risk myelofibrosis and related myeloprol…

• CLINICAL_TRIALS withdrawal · 2016-10-24
  Clinical Trial Update: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis [EARLY_Phase 1]

  Northwestern University’s early-phase trial of siltuximab for myelofibrosis, including primary, post-polycythemia vera, and post-essential t…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2016-09-14
  Clinical Trial Update: Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis [Phase 1]

  This Phase 1 trial of a combination of ruxolitinib phosphate, tacrolimus, and sirolimus to prevent acute graft-versus-host disease in patien…

• CLINICAL_TRIALS withdrawal · 2016-08-12
  Clinical Trial Update: Ruxolitinib in Combination With Autotransplant [NA]

  A clinical trial evaluating ruxolitinib in combination with autotransplant for myelofibrosis has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2016-04-20
  Clinical Trial Update: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders

  A clinical trial (NCT02663648) evaluating a cell cycle regulatory gene study in myeloproliferative neoplasms has been withdrawn by the spons…

• CLINICAL_TRIALS withdrawal · 2012-05-10
  Clinical Trial Update: Palifermin After Haploidentical PBSCT [Phase 2]

  A Phase 2 trial evaluating palifermin after haploidentical peripheral blood stem cell transplantation has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2011-04-28
  Clinical Trial Update: Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation [Phase 2]

  The Phase 2 trial investigating the creation of a bone marrow microenvironment to treat myelodysplastic syndromes in conjunction with alloge…